In this study, targeting TECs by EGCG‐MEND induced anti‐inflammatory effects by suppressing NF‐kB activation, thereby reducing the risk of thrombosis, a leading direct cause of death in patients with cancer (Figure 6) (Created with BioRender.com). This evidence concerns the gene NFKB1 and cancer.